These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 1903730)

  • 1. Hepatic lipase activity during oral and parenteral 17 beta-estradiol replacement therapy: high-density lipoprotein increase may not be antiatherogenic.
    Basdevant A; de Lignieres B; Simon P; Blache D; Ponsin G; Guy-Grand B
    Fertil Steril; 1991 Jun; 55(6):1112-7. PubMed ID: 1903730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in plasma lipoprotein and apolipoprotein composition in relation to oral versus percutaneous administration of estrogen alone or in cyclic association with utrogestan in menopausal women.
    Moorjani S; Dupont A; Labrie F; De Lignieres B; Cusan L; Dupont P; Mailloux J; Lupien PJ
    J Clin Endocrinol Metab; 1991 Aug; 73(2):373-9. PubMed ID: 1649840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of estrogen administration on plasma lipoprotein metabolism in premenopausal females.
    Schaefer EJ; Foster DM; Zech LA; Lindgren FT; Brewer HB; Levy RI
    J Clin Endocrinol Metab; 1983 Aug; 57(2):262-7. PubMed ID: 6408108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Higher values of hepatic lipase activity in postmenopause: relationship with atherogenic intermediate density and low density lipoproteins.
    Berg GA; Siseles N; González AI; Ortiz OC; Tempone A; Wikinski RW
    Menopause; 2001; 8(1):51-7. PubMed ID: 11201516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological effects of estradiol-17 beta in postmenopausal women: oral versus percutaneous administration.
    De Lignieres B; Basdevant A; Thomas G; Thalabard JC; Mercier-Bodard C; Conard J; Guyene TT; Mairon N; Corvol P; Guy-Grand B
    J Clin Endocrinol Metab; 1986 Mar; 62(3):536-41. PubMed ID: 3080464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of postmenopausal hormone replacement with oral and transdermal estrogen on high density lipoprotein metabolism.
    Walsh BW; Li H; Sacks FM
    J Lipid Res; 1994 Nov; 35(11):2083-93. PubMed ID: 7868986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preliminary report: kinetic studies on the modulation of high-density lipoprotein, apolipoprotein, and subfraction metabolism by sex steroids in a postmenopausal woman.
    Hazzard WR; Haffner SM; Kushwaha RS; Applebaum-Bowden D; Foster DM
    Metabolism; 1984 Sep; 33(9):779-84. PubMed ID: 6433146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of testosterone replacement on HDL subfractions and apolipoprotein A-I containing lipoproteins.
    Tan KC; Shiu SW; Pang RW; Kung AW
    Clin Endocrinol (Oxf); 1998 Feb; 48(2):187-94. PubMed ID: 9579231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High density lipoprotein-2 and hepatic lipase: reciprocal changes produced by estrogen and norgestrel.
    Tikkanen MJ; Nikkilä EA; Kuusi T; Sipinen SU
    J Clin Endocrinol Metab; 1982 Jun; 54(6):1113-7. PubMed ID: 7076794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High density lipoprotein subfractions during oral and cutaneous administration of 17 beta-estradiol to menopausal women.
    Fåhraeus L; Wallentin L
    J Clin Endocrinol Metab; 1983 Apr; 56(4):797-801. PubMed ID: 6833462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of hepatic impact of oral and vaginal administration of ethinyl estradiol.
    Goebelsmann U; Mashchak CA; Mishell DR
    Am J Obstet Gynecol; 1985 Apr; 151(7):868-77. PubMed ID: 3920910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins.
    Walsh BW; Schiff I; Rosner B; Greenberg L; Ravnikar V; Sacks FM
    N Engl J Med; 1991 Oct; 325(17):1196-204. PubMed ID: 1922206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of progestogen on lipids, lipoproteins and apolipoproteins during transdermal estrogen replacement therapy with and without medroxyprogesterone acetate.
    Castelo-Branco C; Casals E; Sanllehy C; Duran M; Fortuny A; Vanrell JA
    J Reprod Med; 1996 Nov; 41(11):833-8. PubMed ID: 8951134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipoprotein metabolism in postmenopausal and oophorectomized women.
    Wakatsuki A; Sagara Y
    Obstet Gynecol; 1995 Apr; 85(4):523-8. PubMed ID: 7898827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beneficial effects on serum lipoproteins by 17 beta-oestradiol-dydrogesterone therapy in postmenopausal women; a prospective study.
    van der Mooren MJ; Demacker PN; Thomas CM; Rolland R
    Eur J Obstet Gynecol Reprod Biol; 1992 Nov; 47(2):153-60. PubMed ID: 1459329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of post-menopausal hypercholesterolaemia with estradiol.
    Tikkanen MJ; Kuusi T; Vartiainen E; Nikkilä EA
    Acta Obstet Gynecol Scand Suppl; 1979; 88():83-8. PubMed ID: 230694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women.
    Zegura B; Guzic-Salobir B; Sebestjen M; Keber I
    Menopause; 2006; 13(4):643-50. PubMed ID: 16837886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of probucol on the activity of postheparin plasma lipoprotein lipase and hepatic lipase.
    Miettinen TA; Huttunen JK; Kuusi T; Kumlin T; Mattila S; Naukkarinen V; Strandberg T
    Clin Chim Acta; 1981 Jun; 113(1):59-64. PubMed ID: 6786808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral estrogen replacement therapy in postmenopausal women selectively raises levels and production rates of lipoprotein A-I and lowers hepatic lipase activity without lowering the fractional catabolic rate.
    Brinton EA
    Arterioscler Thromb Vasc Biol; 1996 Mar; 16(3):431-40. PubMed ID: 8630670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of the metabolic tolerance in postmenopausal women over a 1-year period of two hormone replacement therapies containing estradiol in combination with either norgestrel or trimegestone.
    Meuwissen JH; Beijers-De Bie L; Vihtamaki T; Tuimala R; Siseles N; Magaril C; The HS; Houben PW; Murga M; Spielmann D; De Villiers TJ
    Gynecol Endocrinol; 2002 Apr; 16(2):155-62. PubMed ID: 12012627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.